Investor day highlights put Hinge Health in focus

Hinge Health (HNGE) has come into focus after Meridian Small Cap Growth Fund highlighted the company, pointing to a strong quarter, raised full year guidance, and new long term growth and margin targets from its inaugural investor day.

Hinge Health’s recent investor day and raised guidance have come alongside a sharp shift in sentiment, with a 90 day share price return of 65.33% and a 1 year total shareholder return of 67.10% pointing to building momentum, despite a 30 day share price return that is down 9.51% and a 7 day share price return that is down 2.06% from the latest close at US$75.11.

If Hinge Health has caught your attention, it can be helpful to see how other healthcare focused AI platforms are trading right now, starting with 41 healthcare AI stocks.

After a strong rerating and fresh long term targets from management, the real tension for Hinge Health investors now is simple. Does the current price still leave enough upside potential to justify the risks from here?

Most Popular Narrative: 17.3% Undervalued

On the most followed narrative, Hinge Health’s fair value of $90.87 sits above the last close at $75.11. This frames the current valuation debate clearly.

Expansion of integrated digital and in person offerings through HingeSelect and broader provider network build out positions the company to pursue a larger share of MSK and adjacent care pathways, potentially increasing lives under contract and long term revenue per client.

Investors may want to understand what kind of growth and margin profile would justify that higher fair value for Hinge Health. The narrative focuses on a combination of revenue scaling, margin improvement and a future earnings multiple that reflects expectations of staying power.

Result: Fair Value of $90.87 (UNDERVALUED)

However, Hinge Health’s story can change quickly if employer demand cools, or if AI tools like Robin face regulatory or data privacy setbacks that slow adoption.

Another view on Hinge Health’s valuation

The earlier fair value work for Hinge Health leans on analyst earnings forecasts and price targets. A different lens comes from the SWS DCF model, which values the stock at $304.52 per share compared with the current $75.11. That implies a very large potential gap. Is this a genuine opportunity, or a sign that longer term assumptions need extra scrutiny?

Next Steps

With sentiment around Hinge Health clearly mixed, this is a moment to act quickly and test the narrative against your own view. To see what is driving optimism on the company’s potential rewards, start by reviewing the 3 key rewards

Looking for more investment ideas beyond Hinge Health?

If Hinge Health has sharpened your focus, do not stop here. Use the screener tools to spot other opportunities that fit your style before they move.

• Target reliable cash generators and stress test your income plan with the 8 dividend fortresses.
• Hunt for quality companies trading below what their fundamentals suggest they could justify by using the 56 high quality undervalued stocks.
• Prioritise stability and sleep easier at night by focusing on the 89 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.